Corporate Governance - Leadership Team

Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).

Back to Top

Rodney Young joined StemCells, Inc. in September 2005. He has overall responsibility for corporate financial management, financial reporting and controls, investor relations and information technology. Prior to joining StemCells, Mr. Young was Chief Financial Officer and a director of a private pharmaceutical company focused on developing drugs for pediatric indications, where he was responsible for all financial and administrative functions. Before joining the biotechnology industry, Mr. Young was Managing Director and head of health care corporate finance in Europe for SG Cowen Securities, and prior to that, he spent more than a decade at Lehman Brothers, where he was a senior investment banker in both the health care and mergers & acquisitions groups. Mr. Young earned his BA and MBA degrees from the University of Chicago.

Back to Top

Ann Tsukamoto was appointed Executive Vice President, Research and Development in September 2008. She previously served as Vice President, Research and Development. Dr. Tsukamoto has more than 20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells, Inc., the scientific team isolated the human neural stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her PhD from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued U.S. patents related to the human hematopoietic stem cell.

Back to Top

Stewart Craig has more than 20 years of biotechnology industry experience in the research, development, manufacturing, delivery and regulation of cell-based products. Before joining StemCells, Inc. in September 2008, Dr. Craig served as Chief Technology Officer at Progenitor Cell Therapy, LLC (PCT), a contract service provider for the research, development, manufacture and commercialization of cell-based therapies. Prior to joining PCT, Dr. Craig served for six years as Chief Operating Officer at Xcyte Therapies, Inc., a company developing cell-based therapeutic products for the treatment of cancer, immune dysfunction and other diseases. Prior to Xcyte Therapies, Dr. Craig served as Vice President, Development & Operations at Osiris Therapeutics, a mesenchymal stem cell therapy company. During this time, Dr. Craig was also a member of the United States Pharmacopeia Expert Advisory Panel for Cell and Gene Therapy and was a co-author for the initial USP monograph on this subject. From 1994 - 1996, Dr. Craig served as Vice President, Product & Process Development at SyStemix, Inc., the pioneering California-based hematopoietic stem cell and gene therapy company. From 1987 – 1993, Dr. Craig served in various research and development positions at British Biotech, PLC, working on the design, purification and characterization of recombinant therapeutic protein molecules. Dr. Craig received his B.Sc. in Biochemistry and PhD in Physical Biochemistry from the University of Newcastle upon Tyne, UK.

Back to Top

Ken Stratton joined StemCells, Inc. in February 2007. His primary responsibilities include overseeing the Company’s legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. In March 2008, he assumed responsibilities for the Human Resources function. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.

Back to Top

Stephen Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the company, he was an Associate Professor of Neurosurgery at Stanford University and Chief of Pediatric Neurosurgery at the Lucile Salter Packard Children’s Hospital. Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in Neurosurgery at the University of Maryland in 1993. He completed a fellowship in Neuro-Oncology at UCSF Medical Center in San Francisco and a fellowship in Pediatric Neurosurgery at Children's Memorial Hospital in Chicago, Northwestern University. Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery. He is also a Fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains a Consulting Associate Professor appointment (without salary) with the Department of Neurosurgery at Stanford University.

Back to Top

Maria Millan joined StemCells, Inc. in January 2006 and was promoted to Vice President, Head of the Liver Program in December 2006. She is responsible for managing the pre-clinical and clinical development programs for liver indications. Dr. Millan is also serving as the Company’s Acting Chief Medical Officer. She previously was Associate Professor of Surgery, Division of Multi-Organ Transplant, and Director of Pediatric Transplant Programs, Kidney & Liver, at Stanford University School of Medicine, and continues to maintain her appointment as an Adjunct Associate Professor. She received her MD from the New Jersey Medical School and was a Resident and Chief Resident in General Surgery at Harvard Medical School/New England Deaconess Hospital and the Beth Israel Deaconess Medical Center in Boston, Mass. She received a research fellowship in Immunobiology at Harvard Medical School, and held a Fellowship in Multi-Organ Transplant Surgery at Stanford.

Back to Top

Dennise Dalma-Weiszhausz joined StemCells, Inc. in 2007. Dr. Dalma-Weiszhausz is responsible for leading the Company’s Research & Development Services group, assessing technologies and their commercial potential, identifying strategic alliances and overseeing funding initiatives for various research and development programs. She previously was employed as General Manager of Vivonetics, Inc., a start-up biotechnology company focused on molecular beacon technology. Prior to that, Dr. Dalma-Weiszhausz managed marketing and business development for Affymetrix, Inc., a leading biotools company focused on high-throughput whole-genome analyses. Dr. Dalma-Weiszhausz completed her post-doctoral training in the Department of Molecular Biophysics and Biochemistry at Yale University. She earned her PhD and M.Phil. in biochemistry from Albert Einstein College of Medicine, her M.Sci. in Molecular Biophysics and Biochemistry from Yale University and her B.Sc. in Biomedical Research from Universidad Nacional Autonoma de Mexico. She has authored a variety of papers and reviews in the genomics field.

Back to Top

Nobuko Uchida is responsible for the Company’s discovery initiative focusing on identifying new stem or progenitor cells, as well as for characterizing the Company’s human neural stem cell and candidate liver and pancreas stem cells. Dr. Uchida has been with the Company since 1998, and in 1999 she was the first to identify, by a combination of cell surface markers, the human neural stem cell. Dr. Uchida was previously employed at SyStemix, Inc. as a research scientist working on hematopoietic stem cell biology, and has worked in stem cell biology for the past 18 years. Dr. Uchida obtained her PhD in Cancer Biology from Stanford University and completed her post doctoral training in the laboratory of Dr. Irving Weissman at the Stanford University School of Medicine.

Back to Top